Amylyx Pharmaceuticals, Inc. AMLX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -61.6%+39.3pp | -100.9%-114pp | 12.7%— | —— | |
| Return on invested capital | -176.3%+0.1pp | -176.4%-189pp | 12.8%— | —— | |
| Efficiency | |||||
| Asset turnover | 0×-0.2× | 0.2×-0.6× | 0.8×— | —— | |
| Liquidity | |||||
| Current ratio | 14.3×+7.6× | 6.7×+1.0× | 5.7×-2.5× | 8.2×+2.2× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | |
| Per Share | |||||
| Book value per share | $3.23+33.5% | $2.42-61.0% | $6.19+6.4% | $5.82+125% | |
| Valuation | |||||
| Market capitalization | $1.33B+412% | $259.11M-73.9% | $992.34M-58.9% | $2.42B— | |
| Price / book | 4.3×+2.8× | 1.6×-0.7× | 2.3×-4.8× | 7.1×— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Amylyx Pharmaceuticals, Inc.'s profit margins?
- Amylyx Pharmaceuticals, Inc. (AMLX) runs a 100.0% gross margin and a -47349.8% operating margin, with a -45096.2% net margin.
- Where do Amylyx Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Amylyx Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.